Development of amyloid beta detection technique
2015
Université Paris-Sud, Châtenay-Malabry, France
The development of reliable diagnostic tools for Alzheimer's disease is a critical effort to tackle and treat the disease. Several advancements have been made but the available techniques still have inconveniences that limit its clinical potential. Here, a sample pre-treatment for a higher detection sensitivity of different amyloid-beta peptides in cerebrospinal fluid of Alzheimer's patients is proposed. The system is based on a pre-concentration of the samples with magneto-immunocapture, that could achieve x100 concentrations, continued with on-bead fluorescent labelling. The results show that it was possible to concentrate the peptides and this process allowed for more sensitive detection and separation of the peptides, giving the possibility to be better analyzed. Also, different commercial antibodies were tested and a microfluid-based system was developed to allow for rapid sample testing. In this study, the researchers develop a new tool that could improve the detection of amyloid peptides for early diagnosis of Alzheimer's disease and they successfully tested a proof of concept pilot system that could evolve into an easy-handling device to perform high-throughput analysis of patient's samples.
Magneto-immunocapture with on-bead fluorescent labeling of amyloid-β peptides: towards a microfluidized-bed-based operation
Claire Smadja
Added on: 08-26-2021
[1] https://pubs.rsc.org/en/content/articlelanding/2015/an/c5an01179e[2] https://data.jrc.ec.europa.eu/dataset/a8fd26ef-b113-47ab-92ba-fd2be449c7eb
